This study will evaluate safety and clinical benefit of AIGIV used for treatment of patients with systemic anthrax. The study is designed to collect information on safety, clinical benefit (such as extent of anthrax illness and survival) and serum concentrations of AIGIV (for AIGIV pharmacokinetics) and anthrax toxins from sporadic cases of systemic anthrax patients treated with AIGIV.
Confirmed or suspected systemic anthrax patients in the USA or other jurisdictions (if feasible) treated with AIGIV provided by the Centers for Disease Control and Prevention (CDC).
Informed consent/assent (as applicable).
There are no exclusion criteria for subjects enrolling in this study.
Emergent BioSolutions
Lead sponsor
Centers for Disease Control and Prevention
Collaborator
Department of Health and Human Services
Collaborator